Merck, GlaxoSmithKline face hepatitis A vaccine shortage amid U.S. outbreaks

14th November 2017 Uncategorised 0

It was only August when Merck and GlaxoSmithKline had to deal with a global shortage for their hepatitis B vaccines, and now unexpected demand in the U.S. has sent both companies scrambling to cope with a shortage of hep A shots.

More: Merck, GlaxoSmithKline face hepatitis A vaccine shortage amid U.S. outbreaks
Source: fierce